Catalyst Event
Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/12/2026, 12:00:00 AM
Global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS) for 13 early-stage programs in oncology, hematology, and immunology, with a potential value of up to $15.2 billion and upfront/near-term payments of $950 million; the high deal value is estimated to result in a price impact exceeding 10%, scheduled
Korean Translation
브리스톨 마이어스 스퀴브(BMS)와 종양학, 혈액학, 면역학 분야 13개 초기 단계 프로그램에 대한 글로벌 전략적 협력 및 라이선스 계약 체결을 발표할 예정임. 총 계약 규모는 최대 152억 달러, 선급금 및 단기 마일스톤은 9억 5천만 달러에 달하며 대규모 계약 특성상 10% 이상의 주가 영향이 예상됨
Related Recent Events
JD Health International Inc (6618) · Earnings Release
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
8/12/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
6/12/2026, 12:00:00 AM
Veracyte Inc (VCYT) · Other
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
6/10/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Pacific Biosciences of California Inc (PACB) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
6/3/2026, 12:00:00 AM